Maganda Betty Allen, Munishi Castory, Mlyuka Hamu, Mlugu Eulambius M, Mohamedi Juma Ayubu, Mwamwitwa Kissa Watson
School of Pharmacy-Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Tanzania Medicines and Medical Devices Authority, Dar es Salaam, Tanzania.
Hosp Pharm. 2024 Feb;59(1):86-93. doi: 10.1177/00185787231188921. Epub 2023 Aug 1.
The burden of renal diseases is increasing in developing countries like Tanzania. Drug accumulation exposes patients with renal impairment to drug toxicity that may lead to adverse drug reactions, poor adherence to treatment, and increased healthcare costs. There is limited information on the appropriateness of dosage regimen adjustment for patients with renal impairment, particularly in developing countries such as Tanzania. This study aimed to investigate the appropriateness of drug dosing in hospitalized patients with renal impairment in Tanzania. This was a retrospective cross-sectional study. It was conducted between November 2019 and April 2020 amongst hospitalized patients at Muhimbili National Hospital. All enrolled patients had serum creatinine levels ≥1.2 mg/dL and taking at least one drug requiring dosage regimen adjustment. Creatinine clearance was calculated from patient serum creatinine using the Cockcroft-Gault equation. Drug dosing appropriateness was determined by comparing the current practice with tertiary references. The relationship between the patient's baseline characteristics and the rate of dosage regimen adjustment was determined using the X test. Univariate and multivariate logistic regression analysis evaluated the predictors of dosing adjustment. Most of the enrolled patients, 269 (98.9%) had comorbidities. Of the medication orders included in the final analysis, 372 (27%) needed dosage regimen adjustment. Out of the 372 medication orders, not adjusted were 168 (45.2%), inappropriately adjusted 105 (28.2%), and appropriately adjusted were only 99 (26.6%). In this study, 212 (77.9%) patients received at least one drug with an incorrect dosage regimen. Females and those with level 4 renal impairment patients were more likely to have their doses appropriately adjusted compared to their counterparts. In this study, about three-quarters of the patients received at least one drug with an incorrect dosage regimen. Thus, appropriate measures such as the availability of national guidelines and clinical decision support systems for drug dosing adjustment in patients' renal impairment should be in place.
在坦桑尼亚等发展中国家,肾脏疾病的负担正在增加。药物蓄积使肾功能受损患者面临药物毒性风险,这可能导致药物不良反应、治疗依从性差以及医疗成本增加。关于肾功能受损患者剂量方案调整的适宜性信息有限,尤其是在坦桑尼亚这样的发展中国家。本研究旨在调查坦桑尼亚住院肾功能受损患者的药物给药适宜性。这是一项回顾性横断面研究。研究于2019年11月至2020年4月在穆希姆比利国家医院的住院患者中进行。所有纳入的患者血清肌酐水平≥1.2mg/dL,且至少服用一种需要调整剂量方案的药物。使用Cockcroft-Gault方程根据患者血清肌酐计算肌酐清除率。通过将当前做法与三级参考文献进行比较来确定药物给药适宜性。使用X检验确定患者基线特征与剂量方案调整率之间的关系。单因素和多因素逻辑回归分析评估剂量调整的预测因素。大多数纳入的患者,即269例(98.9%)患有合并症。在最终分析中包含的用药医嘱中,372例(27%)需要调整剂量方案。在这372例用药医嘱中,未调整的有168例(45.2%),调整不当的有105例(28.2%),而调整适当的仅有99例(26.6%)。在本研究中,212例(77.9%)患者接受了至少一种剂量方案不正确的药物。与男性和其他肾功能受损程度的患者相比,女性和4级肾功能受损患者的剂量更有可能得到适当调整。在本研究中,约四分之三的患者接受了至少一种剂量方案不正确的药物。因此,应采取适当措施,如制定国家指南以及建立针对肾功能受损患者药物剂量调整的临床决策支持系统。